Cordaneurin
Alternative Names: CanCorda; CordaneurinLatest Information Update: 04 Nov 2017
At a glance
- Originator Neuraxo Biopharmaceuticals
- Developer Spinal Cord Therapeutics
- Class
- Mechanism of Action Collagen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Spinal cord injuries
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Spinal-cord-injuries in European Union (Parenteral, Injection)
- 03 Dec 2010 This programme is still in active development
- 29 Jul 2005 Cordaneurin® will be available for licensing after clinical proof of concept (http://www.neuraxo.com)